Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Oct;58(4):432–436. doi: 10.1038/bjc.1988.235

Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft.

D J Kerr 1, A Rogerson 1, G J Morrison 1, A T Florence 1, S B Kaye 1
PMCID: PMC2246783  PMID: 3207598

Abstract

Niosomes are multilamellar vesicles formed from nonionic surfactants of the alkyl or dialkyl polyglycerol ether class and cholesterol. Adriamycin has been trapped within vesicles prepared from a monoalkyl triglycerol ether and its activity compared with adriamycin solution in human lung tumour cells grown in monolayer and spheroid culture and in tumour xenografted nude mice. The activity of the encapsulated adriamycin in vitro is maintained with similar clonogenic survival curves following treatment of monolayers and identical growth delays following spheroid exposure. The pharmacokinetics of adriamycin are altered in vivo in human lung tumour-bearing nude mice, when it is administered in niosomal form. There is prolonged release of drug from the plasma compartment with significantly lower peak levels; lower peak cardiac adriamycin concentrations with a shorter tissue half-life and decreased cardiac AUC and a greater degree of hepatic metabolism to inactive 7-deoxyaglycones. The tumour peak drug level and AUC was similar irrespective of the mode of administration of adriamycin. The growth delay (i.e. the time taken for the tumour volume to double) was significantly longer for adriamycin (15 days) and niosomal adriamycin (11 days) than for control (5.8 days). It is possible that the therapeutic ratio of adriamycin could be enhanced by administration in niosomal form.

Full text

PDF
432

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azmin M. N., Florence A. T., Handjani-Vila R. M., Stuart J. F., Vanlerberghe G., Whittaker J. S. The effect of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. J Microencapsul. 1986 Apr-Jun;3(2):95–100. doi: 10.3109/02652048609031563. [DOI] [PubMed] [Google Scholar]
  2. Azmin M. N., Florence A. T., Handjani-Vila R. M., Stuart J. F., Vanlerberghe G., Whittaker J. S. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 1985 Apr;37(4):237–242. doi: 10.1111/j.2042-7158.1985.tb05051.x. [DOI] [PubMed] [Google Scholar]
  3. Baillie A. J., Florence A. T., Hume L. R., Muirhead G. T., Rogerson A. The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol. 1985 Dec;37(12):863–868. doi: 10.1111/j.2042-7158.1985.tb04990.x. [DOI] [PubMed] [Google Scholar]
  4. Cummings J., Stuart J. F., Calman K. C. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J Chromatogr. 1984 Nov 9;311(1):125–133. doi: 10.1016/s0378-4347(00)84698-8. [DOI] [PubMed] [Google Scholar]
  5. Deprez-De Campeneere D., Baurain R., Huybrechts M., Trouet A. Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes. Cancer Chemother Pharmacol. 1979;2(1):25–30. doi: 10.1007/BF00253101. [DOI] [PubMed] [Google Scholar]
  6. Forssen E. A., Tökés Z. A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983 Feb;43(2):546–550. [PubMed] [Google Scholar]
  7. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med. 1976 Sep 23;295(13):704–710. doi: 10.1056/NEJM197609232951305. [DOI] [PubMed] [Google Scholar]
  8. Harris A. W., Sephton R. G. Transferrin promotion of 67Ga and 59Fe uptake by cultured mouse myeloma cells. Cancer Res. 1977 Oct;37(10):3634–3638. [PubMed] [Google Scholar]
  9. Kaneko Y. Thyrotropin-daunomycin conjugate shows receptors-mediated cytotoxicity in cultured thyroid cells. Horm Metab Res. 1981 Feb;13(2):110–114. doi: 10.1055/s-2007-1019187. [DOI] [PubMed] [Google Scholar]
  10. Kerr D. J., Wheldon T. E., Kerr A. M., Freshney R. I., Kaye S. B. The effect of adriamycin and 4'-deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids. Br J Cancer. 1986 Sep;54(3):423–429. doi: 10.1038/bjc.1986.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Merry S., Courtney E. R., Fetherston C. A., Kaye S. B., Freshney R. I. Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil. Br J Cancer. 1987 Oct;56(4):401–405. doi: 10.1038/bjc.1987.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Olson F., Mayhew E., Maslow D., Rustum Y., Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol. 1982 Feb;18(2):167–176. doi: 10.1016/0277-5379(82)90060-8. [DOI] [PubMed] [Google Scholar]
  13. Seto M., Umemoto N., Saito M., Masuho Y., Hara T., Takahashi T. Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity. Cancer Res. 1982 Dec;42(12):5209–5215. [PubMed] [Google Scholar]
  14. Szekerke M., Wade R., Whisson M. E. The use of macromolecules as carriers of cytotoxic groups (part II) nitrogen mustard--protein complexes. Neoplasma. 1972;19(3):211–215. [PubMed] [Google Scholar]
  15. Twentyman P. R. Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions. Br J Cancer. 1982 Apr;45(4):565–570. doi: 10.1038/bjc.1982.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Unverferth D. V., Magorien R. D., Leier C. V., Balcerzak S. P. Doxorubicin cardiotoxicity. Cancer Treat Rev. 1982 Jun;9(2):149–164. doi: 10.1016/s0305-7372(82)80014-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES